At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Administration of rituximab and methylprednisolonedrug
Likely dose
Administration of rituximab and methylprednisolone 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
In Brief
A Phase 2 clinical trial evaluating Administration of rituximab and methylprednisolone for Early and Severe Systemic Sclerosis. Completed, enrolled 9 participants across 4 sites.
Detailed Summary
Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both infusions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEarly and Severe Systemic Sclerosis
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartNov 2006
Primary CompletionFeb 2009
TodayJul 2026
First PostedSep 21, 2006
Enrollment StartNov 27, 2006
Primary CompletionFeb 2, 2009
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.8 years ago
Interventions
Administration of rituximab and methylprednisolonedrug
Rituximab: Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use.